All In Biotech

Drug Trial Radar · NCT00211198

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status

Last checked: Nov 20, 2026Latest source record: Mar 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

May 2001

Primary completion

Jan 2005

Study completion Jan 2006

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
Collaborators
Tufts Medical Center; National Cancer Institute (NCI); Ligand Pharmaceuticals
First posted
Sep 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to evaluate how effective ONTAK is in the treatment of cutaneous T-cell Lymphoma (CTCL) and determine whether the presence of a type of protein called CD25 on the cancer cells makes a difference in how the body responds to the treatment. The hypothesis is that there is no difference in response rate for patients whose tumor cells are CD25 positive or negative.

Conditions

  • Lymphoma, T-Cell, Cutaneous

Interventions

  • ONTAK (denileukin difitox, DAB389IL-2)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To estimate response rates (CR + CCR + PR) according to CD25 status (CD25 positive and negative) after 4 cycles of ONTAK.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • The University of Iowa

    Iowa City, Iowa

  • New England Medical Center

    Boston, Massachusetts

  • University Hospitals of Cleveland

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.